HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program.

AbstractPURPOSE:
Poor and underserved women face barriers in receiving timely and appropriate breast cancer care. Patient navigators help individuals overcome these barriers, but little is known about whether patient navigation improves quality of care. The purpose of this study is to examine whether navigated women with breast cancer are more likely to receive recommended standard breast cancer care.
PATIENTS AND METHODS:
Women with breast cancer who participated in the national Patient Navigation Research Program were examined to determine whether the care they received included the following: initiation of antiestrogen therapy in patients with hormone receptor-positive breast cancer; initiation of postlumpectomy radiation therapy; and initiation of chemotherapy in women younger than age 70 years with triple-negative tumors more than 1 cm. This is a secondary analysis of a multicenter quasi-experimental study funded by the National Cancer Institute to evaluate patient navigation. Multiple logistic regression was performed to compare differences in receipt of care between navigated and non-navigated participants.
RESULTS:
Among participants eligible for antiestrogen therapy, navigated participants (n = 380) had a statistically significant higher likelihood of receiving antiestrogen therapy compared with non-navigated controls (n = 381; odds ratio [OR], 1.73; P = .004) in a multivariable analysis. Among the participants eligible for radiation therapy after lumpectomy, navigated participants (n = 255) were no more likely to receive radiation (OR, 1.42; P = .22) than control participants (n = 297).
CONCLUSION:
We demonstrate that navigated participants were more likely than non-navigated participants to receive antiestrogen therapy. Future studies are required to determine the full impact patient navigation may have on ensuring that vulnerable populations receive quality care.
AuthorsNaomi Y Ko, Julie S Darnell, Elizabeth Calhoun, Karen M Freund, Kristin J Wells, Charles L Shapiro, Donald J Dudley, Steven R Patierno, Kevin Fiscella, Peter Raich, Tracy A Battaglia
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 32 Issue 25 Pg. 2758-64 (Sep 01 2014) ISSN: 1527-7755 [Electronic] United States
PMID25071111 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2014 by American Society of Clinical Oncology.
Chemical References
  • Estrogen Receptor Modulators
Topics
  • Breast Neoplasms (drug therapy, radiotherapy, surgery, therapy)
  • Estrogen Receptor Modulators (administration & dosage)
  • Female
  • Health Services Accessibility
  • Healthcare Disparities
  • Humans
  • Mastectomy, Segmental
  • Middle Aged
  • Patient Navigation (methods)
  • Quality of Health Care

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: